Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Benicar

(olmesartan)

ApprovedSmall molecule

Olmesartan is a blood pressure medication that works by relaxing blood vessels so blood can flow more easily and the heart can pump more effectively. It's used to treat high blood pressure in adults and children 6 years and older, and helps prevent serious complications like heart disease, stroke, and kidney damage.[2] Benicar is currently approved and in use across 8 indications[4].[1]

Benicar is one of 215 small molecule programs targeting Cardiovascular Disease. It is currently in Approved.

8

Indications

27

Total Trials

1

Active Trials

214

Competitors

Pipeline

Status by Indication[4][1]

Indication

Cardiovascular DiseaseActive, not recruiting

Essential HypertensionActive, not recruiting

StrokeActive, not recruiting

Paroxysmal Atrial FibrillationActive, not recruiting

HypertensionUnknown

Peripheral Artery DiseaseActive, not recruiting

COVID-19Active, not recruiting

Ischemic StrokeActive, not recruiting

Cardiovascular DiseasePreclinical

Active, not recruiting

Essential HypertensionPhase 3

Active, not recruiting

StrokePhase 2

Active, not recruiting

Paroxysmal Atrial FibrillationPhase 3

Active, not recruiting

HypertensionPreclinical

Unknown

Peripheral Artery DiseaseApproved

Active, not recruiting

COVID-19Phase 3

Active, not recruiting

Ischemic StrokePhase 2

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Benicar

Spikevax

Bnt162b2

COVID-19 Vaccine

Biaxin

Stivarga

Aimovig

Aldactone

Nexavar

Singulair

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hypertension7 trials

RAS Peptide Profiles in Patients With Arterial Hypertension

Completed·IInsel Gruppe AG, University Hospital Bern··NCT02449811·107 enrolled

Effect of Olmesartan on Angiotensin(1-7) Levels and Vascular Functions in Diabetes and Hypertension

Completed·SSeoul National University Bundang Hospital·Phase 4·NCT05189015·80 enrolled

A Study to Evaluate the Effect of LCZ696 on Aortic Stiffness in Subjects With Hypertension

Completed· Novartis logo

Novartis·Phase 2·NCT01870739·115 enrolled

Show 4 more trials

Study of the Safety and Efficacy of LCZ696 on Arterial Stiffness in Elderly Patients With Hypertension

Completed· Novartis logo

Novartis·Phase 2·NCT01692301·454 enrolled

Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)

Completed· Alnylam Pharmaceuticals logo

Alnylam Pharmaceuticals·Phase 2·NCT05103332·663 enrolled

Safety and Efficacy of Azilsartan Medoxomil in Participants With Mild to Moderate Hypertension

Completed· Takeda logo

Takeda·Phase 2·NCT00362115·449 enrolled

Clinical Study for Patients With Hypertension Associated With Dyslipidemia

Completed· Daewoong Pharmaceutical Co. LTD. logo

Daewoong Pharmaceutical Co. LTD.·Phase 3·NCT01764295·150 enrolled

Essential Hypertension6 trials

An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and Olmesartan in Participants With Essential Hypertension.

Completed· Takeda logo

Takeda·Phase 3·NCT00696436·1,291 enrolled

Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Asian Patients With Essential Hypertension

Completed· Novartis logo

Novartis·Phase 3·NCT01785472·1,438 enrolled

Efficacy and Safety of Azilsartan Medoxomil in Participants With Essential Hypertension

Completed· Takeda logo

Takeda·Phase 3·NCT00696241·1,275 enrolled

Show 3 more trials

Efficacy and Safety of Azilsartan in Subjects With Essential Hypertension

Completed· Takeda logo

Takeda·Phase 2·NCT00759551·555 enrolled

Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Japanese Patients With Essential Hypertension

Completed· Novartis logo

Novartis·Phase 3·NCT01599104·1,161 enrolled

Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Elderly Patients With Essential Hypertension

Completed· Novartis logo

Novartis·Phase 3·NCT01615198·588 enrolled

Blood Pressure2 trials

Olmesartan on Ambulatory Blood Pressure Change

Unknown status·NNational Taiwan University Hospital··NCT00854763·100 enrolled

Multi-Omics to Predict the Blood Pressure Response to Antihypertensives

Recruiting·RRadboud University Medical Center·Phase 4·NCT05917275·96 enrolled

Efficacy and Safety1 trial

Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan

Completed· Novartis logo

Novartis·Phase 3·NCT01876368·376 enrolled

Peripheral Artery Disease1 trial

Effect of olmesaRtan on Walking distancE and quaLIty of lifE in Peripheral Artery Disease Patients With Hypertension Treated For Intermittent Claudication (RELIEF)

Terminated·YYonsei University·Phase 4·NCT02373462·1 enrolled

10 more indications

Hypertensive1 trial

Use of Impedance Cardiography and Applanation Tonometry for Prediction of the Antihypertensive Effect of Two Drugs

Completed·—·N/A·NCT03560804·60 enrolled

Paroxysmal atrial fibrillation1 trial

Trial to Investigate the Efficacy of Olmesartan in Paroxysmal Atrial Fibrillation

Completed·AAtrial Fibrillation Network·Phase 3·NCT00098137·422 enrolled

Vascular Inflammation1 trial

Efficacy of Olmesartan on Cerebral Glucose Metabolism, Vascular Inflammation and Adipose Tissue

Unknown status·KKurume University·Phase 4·NCT02996916·100 enrolled

Exercise Training1 trial

Evaluation of Effects of Exercise Training and ARB in DM Patients

Completed·NNational Taiwan University Hospital··NCT01053026·15 enrolled

COVID-191 trial

Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on Outcomes of Coronavirus Infection?

Terminated·UUniversity of British Columbia·Phase 3·NCT04606563·341 enrolled

Cardiovascular Disease1 trial

Cardiovascular Disease (CVD) Risk and Prevention in Early Glucose Intolerance

Completed·EEmory University·N/A·NCT00122447·84 enrolled

Statin1 trial

The Effect of Rosuvastatin and Olmesartan on the Progression of Coronary Atherosclerotic Disease

Unknown status·SSamsung Medical Center·Phase 2·NCT02516826·504 enrolled

Ischemic stroke1 trial

Effect of Olmesartan and Nebivolol on Ambulatory Blood Pressure and Arterial Stiffness in Acute Stage of Ischemic Stroke

Completed·—·Phase 2·NCT03655964·60 enrolled

Interaction1 trial

Investigation of Pharmacokinetic Interaction Between Rosuvastatin and Olmesartan in Healthy Male Volunteers

Completed·SSeverance Hospital·Phase 1·NCT01831479·36 enrolled

Clinical Trial1 trial

Clinical Trial to Evaluate Pharmacokinetic Interaction of ATB-1011 and ATB-1012 in Healthy Adult Volunteers

Completed·AAutotelicbio·Phase 1·NCT04856969·38 enrolled

Sources

References

[1]
ClinicalTrials.gov — 27 trial records for olmesartan. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Benicar drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — olmesartan compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for olmesartan. EMBL-EBI & Wellcome Sanger Institute.
[5]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Type-1 Angiotensin II Receptor Antagonist[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Novartis

Related News